Eosinophilic cholangitis as an indeterminate biliary mimic: A systematic review of outcomes.

Am J Med SciJun 13, 2026 (epub)
Clinical ResearchGastroenterology

Thomas Stirrat, Maximilien Wilkey, Varat Ransibrahmanakul et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 55 studies involving 55 patients with eosinophilic cholangitis (EC), a rare biliary disorder that can mimic malignancies. The review found that 48.7% of cases had a preoperative suspicion of malignancy. Steroids were the primary treatment, leading to symptom resolution in 97.3% of cases and biochemical normalization in 100%.

Key findings

  • 48.7% of patients had a preoperative suspicion of malignancy.
  • Tissue eosinophilic infiltration was reported in 98.1% of cases.
  • Steroids led to symptom resolution in 97.3% of treated patients.
  • Biochemical normalization was achieved in 100% of patients with reported outcomes.

Why it matters

Eosinophilic cholangitis can be misdiagnosed as more serious conditions like primary sclerosing cholangitis or cholangiocarcinoma. Understanding its presentation and effective treatment can improve patient outcomes and reduce unnecessary interventions.

Source

Published in Am J Med Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.